By admin 
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to accelerating the development of clinical-stage therapies for pediatric cancer, has officially announced the appointment of Mark Zafra to its Board of Directors. Zafra, a highly regarded executive with an extensive background in global supply chain management and strategic sourcing, currently serves as the Chief Procurement Officer at LiveRamp. His appointment comes at a critical juncture for the organization as it seeks to bridge the funding gap between laboratory research and clinical trials, a phase often referred to in the medical community as the "Valley of Death." Zafra’s professional expertise, combined with his personal history as a cancer survivor, is expected to provide a unique dual perspective to the board’s strategic oversight and advocacy efforts.
Professional Trajectory and Strategic Expertise
Mark Zafra joins the CureSearch Board with over twenty years of experience in leadership roles within high-growth technology and healthcare sectors. At LiveRamp, a prominent data collaboration platform, Zafra is responsible for the comprehensive management of global strategic sourcing, purchasing, corporate travel, and accounts payable. His role is foundational to the company’s operational efficiency, requiring a sophisticated understanding of how to optimize resources and manage complex vendor ecosystems.
Before his tenure at LiveRamp, Zafra built a robust career through a series of leadership positions at some of the world’s most recognizable corporations. His resume includes significant contributions to Twitter, where he managed large-scale procurement transformations during periods of rapid international expansion. He also held pivotal roles at Allianz Fireman’s Fund, McKesson, Hewlett-Packard (HP), and Agilent Technologies.
Throughout these roles, Zafra has demonstrated a consistent ability to drive innovation through disciplined financial management and supply chain optimization. In the context of a non-profit like CureSearch, these skills are increasingly valuable. Modern philanthropic organizations are moving toward a model of "venture philanthropy," which applies the rigors of corporate investment and supply chain logistics to the pursuit of medical breakthroughs. Zafra’s experience in navigating the complexities of the global market is expected to enhance CureSearch’s ability to manage its research portfolio and ensure that donor contributions are utilized with maximum efficiency.
The State of Pediatric Cancer Research: Supporting Data and Context
The appointment of a procurement and supply chain expert like Zafra highlights the logistical challenges inherent in pediatric oncology. Unlike adult cancers, which often receive significant investment from major pharmaceutical companies due to larger patient populations, childhood cancers are classified as rare diseases. This classification creates a market failure where the financial incentive for private industry to develop new pediatric drugs is often lacking.
According to data from the National Cancer Institute (NCI), while cancer is the leading cause of death by disease among children in the United States, pediatric cancer research receives only approximately 4% of the NCI’s annual budget. This disparity underscores the vital role of organizations like CureSearch. Since its inception, CureSearch has been instrumental in funding research that led to the development of several life-saving treatments, but the path from discovery to the bedside remains fraught with hurdles.
In the United States, more than 15,000 children and adolescents are diagnosed with cancer each year. While survival rates for some forms of the disease, such as certain types of leukemia, have improved significantly over the last few decades, other forms, such as diffuse intrinsic pontine glioma (DIPG) and various pediatric sarcomas, still have very poor prognoses. Furthermore, the survivors of childhood cancer often face long-term health challenges; research indicates that by age 50, more than 99% of childhood cancer survivors have a chronic health problem, and 96% have a severe or life-threatening condition caused by the toxicity of the treatments they received as children.
CureSearch’s strategy focuses specifically on "accelerating" the timeline. By funding researchers who are ready to move into clinical trials, the organization minimizes the time it takes for a new drug to reach the children who need it most. Zafra’s background in procurement and sourcing aligns with this goal of streamlining processes and removing bottlenecks in the development pipeline.
A Personal Commitment to Advocacy and Resilience
Beyond his professional accolades, Mark Zafra’s motivation for joining the CureSearch Board is deeply personal. As a cancer survivor, Zafra possesses a firsthand understanding of the physical and emotional toll the disease takes on patients and their families. This year marks a significant milestone in his journey: the 20th anniversary of his initial cancer diagnosis.
Zafra’s commitment to the cause is exemplified by his participation in the CureSearch Ultimate Hike. This endurance event, set to take place in Jackson, Wyoming, involves trekking 28.3 miles across rugged terrain in a single day. The Ultimate Hike is more than a physical challenge; it is a primary fundraising vehicle for CureSearch, designed to symbolize the arduous journey that children with cancer undergo during treatment.
"It is with great enthusiasm and a deep sense of responsibility that I join CureSearch’s Board of Directors," Zafra stated in a press release. "As a survivor myself, I am a passionate advocate for advancing cancer research and am honored by the opportunity to contribute my skills and experience to a mission that matters deeply to me."
His participation in the hike serves as a testament to the resilience of survivors and highlights the importance of continued research. Funds raised through the Ultimate Hike are directly funneled into cutting-edge research projects, including immunotherapy, targeted molecular therapies, and efforts to reduce the long-term side effects of chemotherapy and radiation.
Leadership and Organizational Response
The leadership at CureSearch has expressed high confidence in Zafra’s ability to contribute to the organization’s long-term vision. Jared Brancazio, the Chair of the CureSearch Board of Directors, emphasized the strategic advantage of bringing a corporate leader with Zafra’s specific skill set into the fold.
"Mark’s professional leadership and personal commitment to advancing cancer research make him an incredible addition to the CureSearch Board," Brancazio said. "We’re honored to have him help guide our work and accelerate our impact."
The Board of Directors at CureSearch is tasked with several critical functions, including financial oversight, strategic planning, and the selection of research projects to fund. The inclusion of a Chief Procurement Officer suggests a move toward more sophisticated operational management. In an era where donors are increasingly demanding transparency and measurable impact, having a board member who specializes in sourcing and efficiency can enhance the organization’s credibility and operational vigor.
Chronology of the Appointment and Future Initiatives
The appointment of Mark Zafra follows a period of strategic reorganization for CureSearch as it adapts to the post-pandemic landscape of medical research.
- Initial Engagement: Zafra began his involvement with CureSearch as a supporter and advocate, eventually moving toward a more formal role as he approached his 20-year survival milestone.
- Board Nomination: Following a rigorous review process by the board’s nominating committee, Zafra was selected for his unique combination of corporate expertise and personal connection to the mission.
- Current Standing: As of late 2024, Zafra has officially assumed his duties on the board, participating in committee meetings and strategic sessions.
- Upcoming Milestones: The Jackson, WY Ultimate Hike will serve as his first major public engagement as a board member, where he will lead a team of hikers and donors.
Looking forward, Zafra is expected to play a key role in CureSearch’s "Catapult Awards," which provide significant funding to high-potential clinical trials. His expertise in contract management and vendor relations may assist the organization in negotiating more favorable terms for research partnerships and ensuring that clinical trials are conducted as efficiently as possible.
Broader Implications for the Non-Profit Sector
Zafra’s move from the C-suite of a major tech firm to the board of a medical non-profit reflects a broader trend in the philanthropic sector. There is a growing recognition that the challenges facing medical research are as much logistical and financial as they are biological. By recruiting leaders from the tech and supply chain sectors, non-profits are better equipped to handle the "business" of saving lives.
In the case of pediatric cancer, the "supply chain" of a drug—from the initial discovery in a university lab to the manufacturing of clinical-grade materials, to the enrollment of patients in a trial—is incredibly fragile. Disruptions in any part of this chain can lead to years of delay. Zafra’s experience in managing global supply chains for companies like HP and Agilent provides him with a framework to identify and mitigate these risks within the pediatric oncology space.
Furthermore, Zafra’s appointment underscores the importance of survivor-led leadership. When those who have experienced the disease are in positions of power, the focus remains steadfastly on the patient experience. His advocacy for "safe and effective" treatment options mirrors a growing demand within the pediatric community for treatments that do not just cure the cancer, but preserve the child’s quality of life into adulthood.
Conclusion
The addition of Mark Zafra to the CureSearch for Children’s Cancer Board of Directors represents a strategic fusion of professional excellence and personal mission. As the organization continues to fund the next generation of pediatric cancer therapies, Zafra’s background in procurement and his perspective as a 20-year survivor will be instrumental. His upcoming participation in the Ultimate Hike in Jackson, WY, serves as a powerful reminder of the physical and metaphorical mountains that remain to be climbed in the fight against childhood cancer. Through his leadership, CureSearch aims to accelerate the pace of discovery, ensuring that the "Valley of Death" no longer stands in the way of life-saving treatments for children worldwide.